Pilot study of Pitolisant, a histamine-3 inverse agonist, as adjunct therapy for refractory restless legs syndrome

CONCLUSION: Pitolisant was generally well tolerated and improved RLS scales. The data suggests more improvement in daytime consequences of RLS compared to lessening of the core RLS symptoms. Controlled trials are justified.

via https://pubmed.ncbi.nlm.nih.gov/40554387/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1lqZ3NPYysePVKsoyz66mDSgu4veDGJwnUBS47TBQPoOuNZY5J&fc=None&ff=20250702011010&v=2.18.0.post9+e462414